Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Recruiting

Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan PharmacokineticsEffect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Sponsor:

medac GmbH

Code:

NCT05534620

Conditions

Acute Myeloid Leukaemia (AML)

Myelodysplastic Syndrome (MDS)

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Treosulfan

Fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by medac GmbH on 2025-03-25.